Publications by authors named "Greg Moeck"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

2,153

Total Likes

350

Extended Reach

2,541,864

Social Features

127
C
Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
Florian M Wagenlehner, Leanne B Gasink, Paul C McGovern, Greg Moeck, Patrick McLeroth, MaryBeth Dorr, Aaron Dane, Tim Henkel,

February 2024

Videos about Article: user user

2 2 125 2 28

View All Article and Social Media Activity
A
Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and in a 7-day hollow fiber infection model.
Lindsay M Avery, Mitchell Edwards, Fan Yi, Greg Moeck, Tsuyoshi Uehara

Antimicrob Agents Chemother· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing the reference broth microdilution MIC method for cefepime-taniborbactam.
Adam Belley, Susan M Cusick, Dan C Pevear, Laura Koeth, Jeanna DiFranco-Fisher, Greg Moeck

J Clin Microbiol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic strains.
Tsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, Mitchell Edwards, Annie Stevenson, Greg Moeck

Antimicrob Agents Chemother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22.
James A Karlowsky, Mark G Wise, Meredith A Hackel, David A Six, Tsuyoshi Uehara, Greg Moeck

J Antimicrob Chemother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARGONAUT-IV: susceptibility of carbapenemase-producing to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.
Michael R Jacobs, Caryn E Good, Ayman M Abdelhamed, Andrew R Mack, Christopher R Bethel, Greg Moeck

Antimicrob Agents Chemother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefepime-taniborbactam demonstrates potent activity vs with .
Maria F Mojica, Elise T Zeiser, Scott A Becka, David A Six, Greg Moeck

Microbiol Spectr· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARGONAUT-III and -V: susceptibility of carbapenem-resistant and multidrug-resistant to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime.
Michael R Jacobs, Ayman M Abdelhamed, Caryn E Good, Andrew R Mack, Christopher R Bethel, Greg Moeck

Antimicrob Agents Chemother· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
Greg Moeck, Leanne B Gasink, Rodrigo E Mendes, Leah N Woosley, MaryBeth Dorr

Antimicrob Agents Chemother· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefepime-Taniborbactam in Complicated Urinary Tract Infection. Reply.
Florian M Wagenlehner, Paul C McGovern, Greg Moeck

N Engl J Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining the activity of cefepime-taniborbactam against complex and isolated from cystic fibrosis patients in the United States.
Maria F Mojica, Elise T Zeiser, Scott A Becka, John J LiPuma, David A Six, Greg Moeck

Antimicrob Agents Chemother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program.
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Greg Moeck

Antimicrob Agents Chemother· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of from a 2018-2020 Global Surveillance Collection.
James A Karlowsky, Mark G Wise, Meredith A Hackel, Daniel C Pevear, Greg Moeck

Antimicrob Agents Chemother· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes.
Robert E Trout, Allison Zulli, Eugen Mesaros, Randy W Jackson, Steven Boyd, Greg Moeck

J Med Chem· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in and Pseudomonas aeruginosa.
Jodie C Hamrick, Jean-Denis Docquier, Tsuyoshi Uehara, Cullen L Myers, David A Six, Greg Moeck

Antimicrob Agents Chemother· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program.
Mark Redell, Greg Moeck, Christopher Lucasti, Stephanie Durso, Cynthia Kennedy

Open Forum Infect Dis· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
G Ralph Corey, Jeffery Loutit, Greg Moeck, Matthew Wikler, Michael N Dudley

Antimicrob Agents Chemother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an Pharmacokinetic/Pharmacodynamic Model.
Adam Belley, Francis F Arhin, Greg Moeck

Antimicrob Agents Chemother· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an Pharmacokinetic/Pharmacodynamic Model of Infection.
Adam Belley, David Lalonde-Séguin, Francis F Arhin, Greg Moeck

Antimicrob Agents Chemother· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.
Debora Sweeney, Audrey Stoneburner, Dean L Shinabarger, Francis F Arhin, Adam Belley, Greg Moeck

J Antimicrob Chemother· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Debora Sweeney, Dean L Shinabarger, Francis F Arhin, Adam Belley, Greg Moeck

Diagn Microbiol Infect Dis· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
Adam Belley, Richard Robson, John L Francis, Dorothy M Adcock, Stefan Tiefenbacher, Greg Moeck

Antimicrob Agents Chemother· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
G Ralph Corey, Francis F Arhin, Matthew A Wikler, Daniel F Sahm, Barry N Kreiswirth, Greg Moeck

Int J Antimicrob Agents· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
Adam Belley, David Lalonde Seguin, Francis Arhin, Greg Moeck

Antimicrob Agents Chemother· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.
Ronald N Jones, Greg Moeck, Francis F Arhin, Michael N Dudley, Paul R Rhomberg

Antimicrob Agents Chemother· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis